efprezimod alfa + tacrolimus + methotrexate

Efprezimod alfa + tacrolimus + methotrexate is a combination regimen comprising **efprezimod alfa**, **tacrolimus**, and **methotrexate**, typically considered for immunomodulatory therapy in settings such as graft-versus-host disease or transplant-related therapy. - **Efprezimod alfa** (CD24Fc, MK-7110) is a recombinant fusion protein acting as an alarmin inhibitor and SIGLEC10 protein stimulant, primarily modulating immune responses via inhibition of inflammatory signaling and reduction of damage-associated molecular pattern (DAMP)-mediated inflammation[4][5]. - **Tacrolimus** is a calcineurin inhibitor that suppresses T-cell activation by inhibiting interleukin-2 transcription. - **Methotrexate** is a folate antagonist that impairs DNA synthesis, often used for immunosuppression and as an antineoplastic agent. This combination would provide targeted immunosuppression through distinct mechanisms: efprezimod alfa blunts innate immune activation, tacrolimus inhibits adaptive T-cell responses, and methotrexate provides antiproliferative and immunomodulatory effects. Such multi-agent regimens may be used off-label or explored in clinical research for severe immune-mediated disorders.

Other names

efprezimod alfa + tacrolimus + methotrexate